natgillin/translations-raw huggingface dataset:
Symptomerne kan være: - tab af taleevne - synsændringer - krampeanfald - forvirring - højt blodtryk
Symptoms include: - loss of speech - change of vision - seizure (fits) - confusion - high blood pressure
% (95 % konfidensinterval)
% (95% CI)
HR = hazard ratio; PFS = progressionsfri overlevelse; a P-værdi = 0,245 (2-sidet).
HR = hazard ratio; PFS = progression-free survival;
Forhøjet bilirubin i blodet ASAT
Uncommon Blood bilirubin increased
Eksfoliativt udslæt Almindelig Alopeci Hudlidelse c
Common Alopecia Skin disorder c
Fald i glucose-niveau i blodet
Blood glucose decreased
Det anbefales derfor i stedet at kombinere pazopanib med et lægemiddel som ikke eller kun minimalt medfører enzym- eller transporter-induktion.
Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended.
Hos gnavere er der også set et nedsat antal corpora lutea, flere cyster og ovarieatrofi.
Decreased corpora lutea, increased cysts and ovarian atrophy have also been noted in rodents.
De vigtigste alvorlige bivirkninger identificeret i RCC- eller STS-studierne var transitorisk iskæmisk attak, iskæmisk apopleksi, myokardieiskæmi, myokardieinfarkt og cerebralt infarkt, kardiel dysfunktion, gastrointestinale perforationer og fistler, QT-forlængelse, Torsade de Pointes samt pulmonal, gastrointestinal og cerebral blødning.
The most important serious adverse reactions identified in the RCC or STS studies were transient ischaemic attack, ischaemic stroke, myocardial ischaemia, myocardial and cerebral infarction, cardiac dysfunction, gastrointestinal perforation and fistula, QT prolongation, Torsade de Pointes and pulmonary, gastrointestinal and cerebral haemorrhage, all adverse reactions being reported in <1% of treated patients.
Forhøjet systolisk blodtryk
Blood pressure diastolic increased Blood pressure systolic increased
Sjælden Interstitiel lungesygdom/pneumonitis†
Interstitial lung disease/pneumonitis†
Kapselformet, lyserød, filmovertrukken tablet med GS JT præget på den ene side.
Capsule-shaped, pink, film-coated tablet with GS JT debossed on one side.
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer): - fordøjelsesbesvær, oppustethed, luft i maven - næseblod - mundtørhed eller sår i munden - infektioner - unormal døsighed - søvnproblemer - brystsmerter, åndenød, smerter i benene og hævede ben/fødder.
Common side effects (may affect up to 1 in 10 people): - indigestion, bloating, flatulence - nose bleed - dry mouth or mouth ulcers - infections - abnormal drowsiness - difficulty sleeping - chest pain, shortness of breath, leg pain, and swelling of the legs/feet.
Abdominalsmerter og smerter i den øvre og nedre del af abdomen b Ødem, perifert ødem, øjenødem, lokaliseret ødem og ansigtsødem c
Abdominal pain, abdominal pain upper and abdominal pain lower b Oedema, oedema peripheral, eye oedema, localised oedema and face oedema c
Forhøjet kreatininniveau i blodet
Blood creatinine increased
Hver filmovertrukken tablet indeholder 200 mg pazopanib (som hydrochlorid).
Each film-coated tablet contains 200 mg pazopanib (as hydrochloride).
Enterokutane fistler
Enterocutaneous fistula
Resultater fra in vitro-forsøg tyder på, at den oxidative metabolisering af pazopanib i humane levermikrosomer primært medieres af CYP3A4, mens CYP1A2 og CYP2C8 spiller en mindre rolle.
In vitro studies suggested that the oxidative metabolism of pazopanib in human liver microsomes is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8.
Hver Votrient 400 mg filmovertrukken tablet indeholder 400 mg pazopanib.
Each Votrient 400 mg film-coated tablet contains 400 mg pazopanib.
Pazopanib skal anvendes med forsigtighed til patienter med risiko for gastrointestinale perforationer eller fistler.
Pazopanib should be used with caution in patients at risk for GI perforation or fistula.
Almindelig Hedeture Venøse tromboemboliske bivirkninger g
Hot flush Venous thromboembolic event g
Amning skal ophøre under behandling med pazopanib.
Breast-feeding should be discontinued during treatment with pazopanib.
Der er set reversibilitet af TMA efter seponering.
Reversal of effects of TMA has been observed after treatment was discontinued.
Samtidig administration af pazopanib (400 mg én gang daglig) og den kraftige CYP3A4- og P-gphæmmer ketoconazol (400 mg én gang daglig) i 5 på hinanden følgende dage resulterede i en stigning på 66 % og 45 % i middelværdierne af henholdsvis AUC(0-24) og Cmax for pazopanib i forhold til administration af pazopanib alene (400 mg én gang daglig i 7 dage).
Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor ketoconazole (400 mg once daily) for 5 consecutive days resulted in a 66% and 45% increase in mean pazopanib AUC(0-24) and Cmax, respectively, relative to administration of pazopanib alone (400 mg once daily for 7 days).
Hver Votrient 200 mg filmovertrukken tablet indeholder 200 mg pazopanib.
Each Votrient 200 mg film-coated tablet contains 200 mg pazopanib.
Hos ca. halvdelen af patienterne fandtes organinvolvering i tre eller flere organer, primært i form af spredning til lungerne (74 %) og/eller til lymfeknuderne
Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74%), and/or lymph nodes (54%) as a metastatic location for disease at baseline.
- hvis du har problemer med skjoldbruskkirtlen.
- if you have thyroid problems.
fedtvæv eller andre væv, som findes rundt om og beskytter organerne.
surround and protect the organs.
Meget almindelig Tumorsmerte
Very common Tumour pain
Pazopanib skal anvendes med forsigtighed til patienter med øget risiko for trombotiske hændelser eller med trombotiske hændelser i anamnesen.
Pazopanib should be used with caution in patients who are at increased risk of thrombotic events or who have had a history of thrombotic events.
Pazopanib hæmmer følgende receptorer: VEGF-receptorer (VEGFR) -1, -2 og -3, trombocytafledte vækstfaktor-receptorer (PDGFR) -α og -β, og stamcellefaktor-receptorer (c-Kit) med IC50-værdier på henholdsvis 10, 30, 47, 71, 84 og 74 nM. I prækliniske forsøg hæmmede pazopanib på dosisafhængig vis den ligandinducerede autofosforylering af receptorerne VEGFR-2, c-Kit og PDGFR-β i celler.
Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor (PDGFR) -α and -β, and stem cell factor receptor (c-KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.
Tegn og symptomer kan omfatte: - tendens til blå mærker - højt blodtryk - feber - forvirring - døsighed - krampeanfald - nedsat produktion af urin
Signs and symptoms may include: - bruising easily - high blood pressure - fever - confusion - drowsiness - seizures (fits) - decrease in urine output
Ved den protokolbestemte endelige analyse af den samlede overlevelse (OS) var den mediane OS 22,9 måneder for patienter, der var randomiseret til pazopanib-armen, og 20,5 måneder for patienter i placebo-armen [HR = 0,91 (95 % konfidensinterval: 0,71-1,16; p = 0,224)].
The median overall survival (OS) data at the protocol-specified final survival analysis were 22.9 months and 20.5 months [HR = 0.91 (95% CI: 0.71, 1.16; p = 0.224)] for patients randomised to the pazopanib and placebo arms, respectively.
Anbefales ikke x 1 - én gang daglig
OD - once daily
- Brug sikker prævention for at undgå at blive gravid, mens du er i behandling med Votrient og i mindst 2 uger efter behandlingen.
- Use a reliable method of contraception while you're taking Votrient, and at least for 2 weeks after, to prevent pregnancy.
Alle patienter skal have taget prøver for nedsat leverfunktion før og under behandling med pazopanib (se pkt.
All patients should have liver function tests to determine whether they have hepatic impairment before starting and during pazopanib therapy (see section 4.4).
Forhøjede aminotransferaser >3 gange den øvre normalgrænse samtidig med forhøjet bilirubin >2 gange den øvre normalgrænse
Transaminase elevations >3 x ULN concurrently with bilirubin elevations >2 x ULN
Din læge vil kontrollere dine leverenzymer, mens du tager Votrient.
Your doctor will be checking your liver enzymes while you are taking Votrient.
Forhøjet niveau af thyroideastimulerende hormon i blodet
Blood thyroid stimulating hormone increased
Baseret på den reducerede eksponering og begrænsede leverkapacitet anbefales pazopanib ikke til patienter med svært nedsat leverfunktion (defineret som total-bilirubin >3 gange den øvre normalgrænse uanset ALAT-niveau) (se pkt.
Based on the diminished exposure and limited hepatic reserve pazopanib is not recommended in patients with severe hepatic impairment (defined as total bilirubin >3 X ULN regardless of any level of ALT) (see section 4.2).
I forsøg med gentagne doser hos gnavere sås en sammenhæng mellem påvirkningen af forskellige væv (knogler, tænder, neglelejer, reproduktive organer, hæmatologiske væv, nyrer og pankreas) og farmakologien af VEGFR-hæmning og/eller afbrydelse af VEGF-signalering.
In repeat dose studies in rodents, effects in a variety of tissues (bone, teeth, nail beds, reproductive organs, haematological tissues, kidney and pancreas) appear related to the pharmacology of VEGFR inhibition and/or disruption of VEGF signalling pathways, with most effects occurring at plasma exposure levels below those observed in the clinic.
Det må ikke indtages med føde og skal tages mindst 1 time før eller 2 timer efter et måltid (se pkt.
It should be taken without food, at least one hour before or two hours after a meal (see section 5.2).
Figur 4 Kaplan-Meier-kurve som illustrerer progressionsfri overlevelse bedømt ved en uafhængig vurdering af den samlede patientpopulation (VEG108844)
Figure 4 Kaplan-Meier Curve for progression-free survival by independent assessment for the overall population (VEG108844)
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer): - højt blodtryk - diarré - kvalme eller opkastning - mavesmerter - appetitløshed - vægttab - smagsforstyrrelser eller ingen smagssans - ømhed i munden - hovedpine - tumorsmerte - manglende energi, følelse af svaghed eller træthed
Very common side effects (may affect more than 1 in 10 people): - high blood pressure - diarrhoea - feeling or being sick (nausea or vomiting) - stomach pain - loss of appetite - weight loss - taste disturbance or loss of taste - sore mouth - headache - tumour pain - lack of energy, feeling weak or tired - changes in hair colour - unusual hair loss or thinning - loss of skin pigment
Den maksimalt tolererede pazopanibdosis hos patienter med moderat nedsat leverfunktion (defineret som forhøjet bilirubin >1,5-3 gange den øvre normalgrænse uanset ALAT-niveau) var 200 mg én gang daglig.
The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin >1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily.
Votrient skal tages mindst 1 time før et måltid eller 2 timer efter et måltid (se punkt 3).
Take it at least two hours after a meal or one hour before a meal (see section 3).
QT-forlængelse Forhøjet aminotransferaseniveau
Alanine aminotransferase increased
Kontroller leverfunktionen ugentligt, indtil aminotransferase-niveauet vender tilbage til grad 1 eller udgangsniveauet.
Continue on pazopanib with weekly monitoring of liver function until transaminases return to Grade 1 or baseline.
Nedsat trombocyttal QT-forlængelse
Electrocardiogram QT prolonged
Generaliseret pruritus 2 (<1 %) 1 (<1 %) 0 Generaliseret udslæt
Pruritus generalised 2 (<1%) Rash generalised Rash papular
800 mg pazopanib én gang daglig er den anbefalede dosis til patienter med let afvigende leverfunktionsprøver målt i serum (defineret enten som normalt bilirubin-niveau og alle grader af forhøjet alaninaminotransferase (ALAT) eller forhøjet bilirubin-niveau (>35 % konjugeret) op til 1,5 gange den øvre normalgrænse uanset ALATniveau).
800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (defined either as normal bilirubin and any degree of alanine aminotransferase (ALT) elevation or as an elevation of bilirubin (>35% direct) up to 1.5 x upper limit of normal (ULN) regardless of the ALT value).
800 mg x 1
800 mg OD
Hyperhidrose Sygdom i neglene Pruritus
Hyperhydrosis Nail disorder
Du vil blive undersøgt for hjerteproblemer, mens du er i behandling med Votrient.
You will be checked for any heart problems while you are taking Votrient.
Almindelig Hypopigmentering af huden
Skin hypopigmentation Dry skin
Cerebralt infarkt
Cerebrovascular accident
Figur 5 Kaplan-Meier-kurve som illustrerer progressionsfri overlevelse ved STS bedømt ved en uafhængig vurdering af den samlede patientpopulation (VEG110727)
Figure 5 Kaplan-Meier Curve for Progression-Free Survival in STS by Independent Assessment for the Overall Population (VEG110727)
Der skal udvises forsigtighed ved administration af pazopanib til patienter med let til moderat nedsat leverfunktion, og patienterne skal monitoreres nøje for tolerabilitet.
Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and close monitoring of tolerability.
Vaginal blødning 3 (<1 %) 0 Metrorragi
Uncommon Menorrhagia Vaginal haemorrhage 3 (<1%) Metrorrhagia
Median steady-state pazopanib Cmax og AUC(0-24) hos patienter med let afvigende leverparametre (defineret som enten normalt bilirubin-niveau og alle grader af forhøjet ALAT eller forhøjet bilirubin-niveau op til 1,5 gange den øvre normalgrænse uanset ALAT-niveau) efter administration af 800 mg pazopanib én gang daglig, svarede til medianen hos patienter med normal leverfunktion (se tabel 7).
The median steady-state pazopanib Cmax and AUC(0-24) in patients with mild abnormalities in hepatic parameters (defined as either normal bilirubin and any degree of ALT elevation or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value) after administration of 800 mg once daily are similar to the median in patients with normal hepatic function (see Table 7).
Reproduktionstoksicitet er påvist i dyreforsøg (se pkt.
Studies in animals have shown reproductive toxicity (see section 5.3).
Medianværdier for steady-state Cmax og AUC(0-24) efter administration af 200 mg pazopanib én gang daglig til patienter med moderat nedsat leverfunktion var henholdsvis ca. 44 % og 39 % af de tilsvarende medianværdier efter administration af 800 mg én gang daglig til patienter med normal leverfunktion (se tabel 7).
The median steady-state Cmax and AUC(0-24) values after administration of 200 mg pazopanib once daily in patients with moderate hepatic impairment were approximately 44% and 39%, of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function, respectively (see Table 7).
Endvidere sås stigninger på 33 % til 64 % i forholdet mellem koncentrationen af dextromethorphan og dextrorphan i urinen efter oral administration af dextromethorphan (CYP2D6-substrat).
Pazopanib resulted in an increase of approximately 30% in the mean AUC and Cmax of midazolam (CYP3A4 probe substrate) and increases of 33% to 64% in the ratio of dextrometrophan to dextrophan concentrations in the urine after oral administration of dextromethorphan (CYP2D6 probe substrate).
Hvis du har taget for meget Votrient
If you take more Votrient than you should
Hypomagnesiæmi
Hypothyroidism
g Kardiel dysfunktion - inkluderer venstre ventrikel dysfunktion, hjerteinsufficiens og restriktiv kardiomyopati h
g Cardiac dysfunction events - includes Left ventricular dysfunction, Cardiac failure and Restrictive cardiomyopathy h Frequency is based on adverse events reported by investigators.
Hændelser med kardiel dysfunktion, såsom kongestiv hjerteinsufficiens og nedsat LVEF, er set i kliniske studier med pazopanib (se pkt 4.8).
In clinical studies with pazopanib, events of cardiac dysfunction such as congestive heart failure and decreased LVEF have occurred (see section 4.8).
800 mg pazopanib én gang daglig er den anbefalede dosis til patienter med let afvigende leverfunktionsprøver målt i serum (enten normalt bilirubin-niveau og alle grader af forhøjet ALAT eller forhøjet bilirubin op til 1,5 gange den øvre normalgrænse uanset ALAT-niveau).
800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (either normal bilirubin and any degree of ALT elevation or elevation of bilirubin up to 1.5 x ULN regardless of the ALT value).
Abdominalsmerter, smerter i den øvre del af abdomen og gastrointestinale smerter b Ødem, perifert ødem og øjenlågsødem c
The following terms have been combined: a Abdominal pain, abdominal pain upper and gastrointestinal pain b Oedema, oedema peripheral and eyelid oedema c
Da pazopanib på grund af virkningsmekanismen i alvorlig grad påvirker organvækst og udvikling i den tidlige post-natale periode hos gnavere (se pkt.
Because the mechanism of action of pazopanib can severely affect organ growth and maturation during early post-natal development in rodents (see section 5.3), pazopanib should not be given to paediatric patients younger than 2 years of age.
Responsrate (CR+PR) % (95 % konfidensinterval) Responsvarigheden Median (uger) (95 % konfidensinterval)
Response rate (CR+PR) % (95% CI) Duration of response Median (weeks) (95% CI) 38.9 (16.7, 40.0)
Myokardiel dysfunktion forekom hos 13 % (47/362) af patienterne i pazopanib-armen sammenlignet med 11 % (42/369) af patienterne i sunitinib-armen.
Myocardial dysfunction occurred in 13% (47/362) of subjects in the pazopanib arm compared to 11% (42/369) of subjects in the sunitinib arm. Congestive heart failure was observed in 0.5% of subjects in each treatment arm. Congestive heart failure was reported in 3 out of 240 subjects (1%) in the Phase III VEG110727 STS study.
Bløddelssarkom (STS)
Soft-tissue sarcoma (STS)
Medianværdier for steady-state Cmax og AUC(0-24) efter administration af 200 mg pazopanib én gang daglig til patienter med svært nedsat leverfunktion var henholdsvis ca. 18 % og 15 % af de tilsvarende medianværdier efter administration af 800 mg én gang daglig til patienter med normal leverfunktion (se tabel 3).
The median steady-state Cmax and AUC(0-24) values after administration of 200 mg pazopanib once daily in patients with severe hepatic impairment were approximately 18% and 15%, of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function.
HR = hazard ratio; ITT = intent to treat; PFS = progressionsfri overlevelse; CR = komplet respons; PR = delvist respons; OS = samlet overlevelse *Samlet overlevelse ved de respektive histologiske STS-undertyper (leiomyosarkom, synovialsarkom og “andre” STS) skal tolkes med forsigtighed på grund af det lille antal forsøgspersoner og det store konfidensinterval.
OS = overall survival * Overall survival for the respective STS histological subgroups (leiomyosarcoma, synovial sarcoma and “Other” STS) should be interpreted with caution due to the small number of subjects and wide confidence intervals
30 filmovertrukne tabletter 60 filmovertrukne tabletter
30 film-coated tablets 60 film-coated tablets
Det anbefales at måle LVEF inden behandlingsstart og periodisk under behandlingen hos patienter med risiko for kardiel dysfunktion.
Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction.
Patienter, som udvikler TMA, skal seponere pazopanib permanent.
Patients developing TMA should permanently discontinue treatment with pazopanib.
Normal leverfunktion
Normal hepatic function
Pazopanib anbefales ikke til patienter med svært nedsat leverfunktion (defineret som total-bilirubin >3 gange den øvre normalgrænse uanset ALAT-niveauet).
Pazopanib is not recommended in patients with severe hepatic impairment (defined as total bilirubin >3 x ULN regardless of the ALT value).
Proteinuri er rapporteret i kliniske studier med pazopanib.
In clinical studies with pazopanib, proteinuria has been reported.
Forhøjede aminotransferaser >8 gange den øvre normalgrænse
Transaminase elevation of >8 x ULN
Myokardieinfarkt, myokardieiskæmi, iskæmisk apopleksi og transitorisk iskæmisk attak er observeret i kliniske studier med pazopanib (se pkt.
In clinical studies with pazopanib, myocardial infarction, myocardial ischaemia, ischaemic stroke and transient ischaemic attack were observed (see section 4.8).
Der findes ingen specifik antidot, som kan anvendes i tilfælde af overdosering med pazopanib.
There is no specific antidote for overdose with pazopanib and treatment of overdose should consist of general supportive measures.
Udspilet abdomen 36 (3 %) Sår i munden
Common Abdominal distension 16 (4%) Dry mouth
Gastrointestinal blødning
Gastrointestinal haemorrhage
Votrient 200 mg filmovertrukne tabletter er kapselformede og lyserøde med “GS JT” trykt på den ene side.
What Votrient looks like and contents of the pack Votrient 200 mg film-coated tablets are capsule-shaped, pink with “GS JT” marked on one side.
Nedsat LVEF sås hos 11 % (11/140) og 3 % (1/39) i henholdsvis pazopanib-armen og placebo-armen hos de forsøgspersoner, der fik målt LVEF post baseline og ved followup.
Decreases in LVEF in subjects who had post-baseline and follow-up LVEF measurement were detected in 11% (15/140) in the pazopanib arm, compared with 3% (1/39) in the placebo arm.
Derfor skal pazopanib administreres mindst 1 time før eller 2 timer efter et måltid (se pkt.
Therefore, pazopanib should be administered at least two hours after food or at least one hour before food (see section 4.2).
Øsofagal blødning 1 (<1 %) 0
Cerebral infarction 1 (<1%)
Reproduktionstoksicitet er påvist i prækliniske dyreforsøg (se pkt.
Pre-clinical studies in animals have shown reproductive toxicity (see section 5.3).
En stigning i serumniveauet af aminotransferaser (ALAT, aspartataminotransferase [ASAT]) og bilirubin er observeret i kliniske studier med pazopanib (se pkt.
In clinical studies with pazopanib, increase in serum transaminases (ALT, aspartate aminotransferase [AST]) and bilirubin were observed (see section 4.8).
Almindelig Muskuloskeletale smerter 35 (9 %) 2 (<1 %) 0 Myalgi
Common Musculoskeletal pain 35 (9%) Myalgia Muscle spasms Uncommon Arthralgia
X-akse: Måneder, Y-akse: Progressionsfri overlevelse, Pazopanib --- (n = 290), median 9,2 måneder; Placebo ------- (n = 145), median 4,2 måneder; Hazard ratio = 0,46; 95 % konfidensinterval (0,34-0,62), P < 0,0000001
x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 290) Median 9.2 months; Placebo ------- (N = 145) Median 4.2 months; Hazard Ratio = 0.46, 95% CI (0.34, 0.62), P <0.0000001
Du vil blive undersøgt for mængden af skjoldbruskkirtelhormon i blodet, mens du er i behandling med Votrient.
You will be checked for thyroid hormone levels while you are taking Votrient.
X-akse: Måneder, Y-akse: Progressionsfri overlevelse, Pazopanib --- (n = 155), median 11,1 måneder; Placebo ------- (n = 78), median 2,8 måneder; Hazard ratio = 0,40; 95 % konfidensinterval (0,27-0,60), P < 0,0000001
x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 155) Median 11.1 months; Placebo -------- (N = 78) Median 2.8 months; Hazard Ratio = 0.40, 95% CI (0.27, 0.60), P <0.0000001
Samtidig brug af pazopanib og simvastatin øger risikoen for stigning i ALAT-niveauet (se pkt.
Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations (see section 4.5) and should be undertaken with caution and close monitoring.
Før behandlingen med pazopanib indledes, skal patienter med hypotyroidisme have standardbehandling i henhold til almindelig medicinsk praksis.
Baseline laboratory measurement of thyroid function is recommended and patients with hypothyroidism should be treated as per standard medical practice prior to the start of pazopanib treatment.
hvilken medicin du tager for at nedsætte mængden af mavesyre (f.eks. protonpumpehæmmer,
The type of medicine that you are taking to reduce your stomach acid (e.g. proton pump inhibitor, H2 antagonists or antacids) may affect how Votrient is taken.